High Prevalence of Myositis-Specific and Associated Antibodies in Patients with Pulmonary Hypertension.
Rachid TobalJudith PotjewijdDaan P C van DoornVanessa van EmpelJan G M C DamoiseauxPieter van PaassenPublished in: Diagnostics (Basel, Switzerland) (2024)
Pulmonary hypertension (PH) is a serious condition linked to immune-system dysfunction. Myositis-specific/associated antibodies (MSAs/MAAs) play a role in idiopathic inflammatory myopathy (IIM) and interstitial lung disease (ILD), but their significance in PH remains unclear. We believe the presence of these antibodies may be underestimated. This study analyzed adult PH patients without pre-existing IIM for MSA/MAA prevalence using a line-blot assay. We compared PH patients with and without ILD signs to a cohort clinically suspected of IIM/ILD ( n = 558). Our PH cohort ( n = 121) showed a significantly higher prevalence of overall weak positive MSAs/MAAs and positive overlap syndrome-associated MAAs than the suspected IIM/ILD group ( p < 0.001). Notably, MSAs/MAAs were found in PH patients both with and without ILD, though more prevalent in those with ILD. Anti-synthetase and anti-overlap syndrome antibodies were the most common. Our study is the first to systematically show a high MSA/MAA prevalence in PH without IIM presentation. This highlights the need to consider PH when diagnosing MSA/MAA-associated conditions. We recommend MSA/MAA screening for newly diagnosed PH, especially in those with ILD, for early detection and potential immunomodulatory treatment. Further research should explore the link between MSAs/MAAs and PH, and the value of monitoring patients with weak MSA/MAA positivity over time.
Keyphrases
- interstitial lung disease
- systemic sclerosis
- newly diagnosed
- rheumatoid arthritis
- idiopathic pulmonary fibrosis
- pulmonary hypertension
- end stage renal disease
- ejection fraction
- oxidative stress
- risk factors
- chronic kidney disease
- pulmonary artery
- pulmonary embolism
- young adults
- case report
- prognostic factors
- risk assessment
- high throughput
- late onset
- myasthenia gravis